- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03926728
Safety and Immunogenicity of a Chlamydia Vaccine CTH522 (CHLM-02)
A Phase I, Double-blind, Parallel, Randomised and Placebo-controlled Trial Investigating the Safety and Immunogenicity of a Chlamydia Vaccine, CTH522, in Healthy Adults
Study Overview
Status
Conditions
Detailed Description
This trial is a phase I, double-blind, parallel, randomised, and placebo-controlled trial of the chlamydia vaccine CTH522 in healthy adults.
It is planned to randomly assign 66 subjects into six cohorts. Cohorts A-D investigate CTH522-CAF01 administered IM in two doses (85 μg and 15 μg). Cohort E investigates CTH522-CAF09b administered IM in one dose (85 μg). Cohort F is the placebo group. The enrolled subjects will complete 12 trial visits. All subjects in the active groups (cohort A-E) will receive three IM injections of the adjuvanted CTH522 and some (cohort B and C) will receive the non-adjuvanted CTH522 via the TO or ID route (given at the same time as the 2nd and 3rd IM vaccinations). All active groups will receive TO administration as a boost at Day 140 of either the non-adjuvanted CTH522 (12 μg in each eye) or placebo.
- Cohort A will receive three IM vaccination of 85μg CTH522-CAF01. This cohort is divided into two groups: A1 will receive ID placebo at Day 28 + Day 112, and TO placebo at Day 140, while A2 will receive TO placebo at Day 28 + Day 112, and non-adjuvanted TO CTH522 boost at Day 140.
- Cohort B will receive three IM vaccinations of 85 μg CTH522-CAF01. This cohort is divided into two groups: B1 will receive TO vaccination of the non-adjuvanted CTH522 at Day 28 and 112 and TO placebo at Day 140, while B2 will receive the same for Day 28 and 112, but non-adjuvanted TO CTH522 boost at Day 140. The two additional TO doses of CTH522 (12 μg in each eye) are administered in each eye. The rationale for this schedule is to investigate the impact of simultaneous TO administration of the antigen on the immunogenicity results.
- Cohort C will receive three IM vaccinations of 85 μg CTH522-CAF01. This cohort is divided into two groups: C1 will receive ID vaccination of the non-adjuvanted 24 μg CTH522 at Day 28 and 112 and TO placebo at Day 140, while C2 will receive the same for Day 28 and 112, but TO 12 μg CTH522 boost in each eye at Day 140. The rationale for this schedule is to investigate the impact of simultaneous ID administration of the antigen on the immunogenicity results.
- Cohort D will receive three IM vaccinations of 15 μg CTH522-CAF01. The rationale for the A and D cohorts is to investigate the impact of the two IM CTH522 doses on the immunogenicity results.
- Cohort E will receive three IM vaccinations of 85 μg CTH522-CAF09b. The rationale for the A and E cohorts is to investigate the impact of the adjuvant on the immunogenicity results.
- Cohort F will receive only placebo in the form of 0.9% NaCl saline (IM, ID and TO).
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, W12
- NIHR Imperial Center for Translational and Experimental Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
IC1: Healthy males and females between 18-45 years old on the day of the first vaccination IC2: Has been properly informed about the trial and signed the consent form IC3: Is willing and likely to comply with trial procedures IC4: Is prepared to grant authorised persons access to his/her trial-related medical record IC5: Is willing to use acceptable contraceptive measures during the trial (two weeks before and two weeks after the trial). Heterosexually active female capable of becoming pregnant must agree to use hormonal contraception, intrauterine device, intrauterine hormonereleasing system, or to complete abstinence from at least two weeks before the first vaccination until at least two weeks after the last. Complete abstinence (defined as refraining from heterosexual intercourse) must be in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods), withdrawal and progestogen-only oral hormonal contraception where inhibition of ovulation is not the primary mode of action are not acceptable methods of contraception
Exclusion criteria:
EX1: Is positive for C. trachomatis via urine PCR or has a known history of C. trachomatis EX2: Is positive for gonorrhoea via urine PCR test, or HIV, hepatitis B/C, syphilis via blood tests EX3: Has a significant active disease such as cardiac, liver, immunological, neurological, psychiatric or clinically significant abnormality of haematological or biochemical parameters EX4: Has BMI ≥ 35 kg/m2 EX5: Is currently participating in another clinical trial with an investigational or noninvestigational drug or device, or was treated with an investigational drug within 28 days before the first vaccination EX6: Has received, or plans to receive, any immunisation within 14 days of the start of the trial or during the trial immunisations EX7: Is currently receiving treatment with systemic immunosuppressive agents. Topical steroids are allowed unless applied to the IM or ID injection site EX8: Has a condition which in the opinion of the investigator is not suitable for participation in the trial EX9: Is known or confirmed to have an allergy to any of the vaccine constituents EX10: Is unable to refrain from the use of contact lenses. Contact lenses should be avoided two days before TO administration and for seven days later (longer if any ongoing local eye AE) EX11: Has any evident ocular disease upon ophthalmoscopic exam at screening or any medical history of ocular disease that, in the opinion of the investigator, may impact the subject's participation in the trial EX12: Is pregnant (positive pregnancy test) or breastfeeding or not willing to use contraception during the trial EX13: Has confirmed a history of pelvic inflammatory disease or significant gynaecological diseases
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort A - 85µg CTH522-CAF01
Cohorts A will receive three IM vaccination of 85µg CTH522-CAF01.
This cohort is divided into two groups: A1 will receive placebo at DAY 28 + Day 112 + Day 140, while A2 will receives placebo at Day 28 + Day 112, but non-adjuvanted TO CTH522 boost at Day 140.
|
On-site reconstitution of IMPs is performed by mixing 85 microgram CTH522 with CAF01.
The preferred for IM is in the non-dominant deltoid muscle.
IM injection will be performed with a 1-2 ml polypropylene Luer-Lok™ syringe via 23-25-gauge needle.
The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor.
The identity of the trial vaccine administered will remain unknown to the subject during the trial.
24 microgram CTH522 (12 microgram in each eye) TO administrations will be performed using a Gilson positive displacement pipette.
The identity of vaccine will be known to the clinical site staff dispensing/administrating the trial vaccine to the subject and by the unblinded trial monitor.
The identity of the trial vaccine administered will remain unknown to the subject during the trial.
Placebo only given as IM, ID and TO
|
Experimental: Cohort B - 85µg CTH522-CAF01+ TO CTH522
Cohort B will receive three IM vaccination of 85 µg CTH522-CAF01.
This cohort is divided into two groups: B1 will receive TO vaccination of the non-adjuvanted CTH522 at Day 28 + Day 112 and TO placebo at Day 140, while B2 will receive the same for Day 28 + Day 112, but non-adjuvanted TO CTH522 boost at Day 140.
The two additional doses TO CTH522 (12µg) is administered in each eye.
The rationale for this cohort is to investigate the impact of simultaneous TO administration of the antigen on the immunogenicity results obtained.
|
On-site reconstitution of IMPs is performed by mixing 85 microgram CTH522 with CAF01.
The preferred for IM is in the non-dominant deltoid muscle.
IM injection will be performed with a 1-2 ml polypropylene Luer-Lok™ syringe via 23-25-gauge needle.
The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor.
The identity of the trial vaccine administered will remain unknown to the subject during the trial.
24 microgram CTH522 (12 microgram in each eye) TO administrations will be performed using a Gilson positive displacement pipette.
The identity of vaccine will be known to the clinical site staff dispensing/administrating the trial vaccine to the subject and by the unblinded trial monitor.
The identity of the trial vaccine administered will remain unknown to the subject during the trial.
Placebo only given as IM, ID and TO
|
Experimental: Cohort C - 85µg CTH522-CAF01+ID CTH522
Cohort C will receive three IM vaccination of 85 µg CTH522-CAF01.
This cohort is divided into two groups: C1 will receive ID vaccination of the non-adjuvanted CTH522 at Day 28 + Day 12 and TO placebo at Day 140, while C2 will receive the same for Day 28 + Day 112, but TO CTH522 boost at Day 140.
The two additional doses of non-adjuvanted CTH522 (24µg) is administered ID.
The rationale for this cohort is to investigate the impact of simultaneous ID administration of the antigen on the immunogenicity results obtained.
|
On-site reconstitution of IMPs is performed by mixing 85 microgram CTH522 with CAF01.
The preferred for IM is in the non-dominant deltoid muscle.
IM injection will be performed with a 1-2 ml polypropylene Luer-Lok™ syringe via 23-25-gauge needle.
The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor.
The identity of the trial vaccine administered will remain unknown to the subject during the trial.
Placebo only given as IM, ID and TO
24 microgram CTH522 given ID is in the non-dominant deltoid muscle.
ID with a 1 ml syringe via a 26-28 gauge needle using a NanoPass device or similar.
The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor.
The identity of the trial vaccine administered will remain unknown to the subject during the trial.
|
Experimental: Cohort D - 15µg CTH522-CAF01
Cohort D is the same as cohort A except that the dose for CTH522-CAF01 is 15µg.
|
On-site reconstitution of IMPs is performed by mixing 85 microgram CTH522 with CAF01.
The preferred for IM is in the non-dominant deltoid muscle.
IM injection will be performed with a 1-2 ml polypropylene Luer-Lok™ syringe via 23-25-gauge needle.
The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor.
The identity of the trial vaccine administered will remain unknown to the subject during the trial.
24 microgram CTH522 (12 microgram in each eye) TO administrations will be performed using a Gilson positive displacement pipette.
The identity of vaccine will be known to the clinical site staff dispensing/administrating the trial vaccine to the subject and by the unblinded trial monitor.
The identity of the trial vaccine administered will remain unknown to the subject during the trial.
Placebo only given as IM, ID and TO
|
Experimental: Cohort E - 85µg CTH522-CAF09b
Cohort E is the same as cohort A except that the adjuvant is CAF09b and not CAF01.
The rationale for the A, D and E cohorts is to investigate the impact of the CTH522 dose and adjuvant on the immunogenicity results.
|
Placebo only given as IM, ID and TO
On-site reconstitution of IMPs is performed by mixing 85 microgram CTH522 with CAF09b.
The preferred for IM is in the non-dominant deltoid muscle.
IM injection will be performed with a 1-2 ml polypropylene Luer-Lok™ syringe via 23-25-gauge needle.
The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor.
The identity of the trial vaccine administered will remain unknown to the subject during the trial.
|
Placebo Comparator: Cohort F - Placebo
Cohort F will receive only placebo in form of 0.9% NaCl saline.
|
Placebo only given as IM, ID and TO
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Local injection reactions
Time Frame: Visit 2 (Day 0) to Visit 12 (Day 238)
|
Local injection site reactions after intramuscular and intradermal vaccination
|
Visit 2 (Day 0) to Visit 12 (Day 238)
|
Local ocular reactions
Time Frame: Visit 2 (Day 0) to Visit 12 (Day 238)
|
Local ocular reactions after topical ocular vaccination
|
Visit 2 (Day 0) to Visit 12 (Day 238)
|
Systemic reactions
Time Frame: Visit 2 (Day 0) to Visit 12 (Day 238)
|
Systemic reactions after vaccinations
|
Visit 2 (Day 0) to Visit 12 (Day 238)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Secondary - immunogenicity
Time Frame: Visit 2 (Day 0) to Visit 12 (Day 238); except for Visit 10 (Day 143)
|
Seroconversion for anti-CTH522 IgG at any time points after vaccinations of CTH522
|
Visit 2 (Day 0) to Visit 12 (Day 238); except for Visit 10 (Day 143)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exploratory - immunogenicity
Time Frame: Visit 2 (Day 0) to Visit 12 (Day 238); except for Visit 3 (Day 14) for ocular strip
|
Systemic and ocular antibodies: cell-mediated immune response, antibody responses measured by T- and B-cell Elispot, serum neutralising antibodies against serovars D-G. Isolation and characterisation of CTH522-antigen-specific memory B-cells in the systemic compartments (dependent on the elicited specific memory T- and B-cell numbers) |
Visit 2 (Day 0) to Visit 12 (Day 238); except for Visit 3 (Day 14) for ocular strip
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Alvaro Borges, MD, Statens Serum Institut
- Principal Investigator: Katrina Pollock, MD, Imperial Clinical Tesearch Facility Hammersmith Hospital
- Study Chair: Lina S Stoey, MPH, Statens Serum Institut
- Study Chair: Pernille N Tingskov, BS, Statens Serum Institut
- Study Chair: Rebecca B Dohn, Pharm, Statens Serum Institut
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Communicable Diseases
- Sexually Transmitted Diseases
- Eye Diseases
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Conjunctivitis
- Conjunctival Diseases
- Corneal Diseases
- Chlamydiaceae Infections
- Sexually Transmitted Diseases, Bacterial
- Eye Infections, Bacterial
- Eye Infections
- Conjunctivitis, Bacterial
- Chlamydia Infections
- Trachoma
Other Study ID Numbers
- CHLM-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Trachoma
-
University of California, San FranciscoNational Eye Institute (NEI); Institut National de Recherche Biomédicale. Kinshasa...Not yet recruitingTrachomaCongo, The Democratic Republic of the
-
Emory UniversityThe Carter CenterSuspended
-
University of California, San FranciscoCompleted
-
Johns Hopkins UniversityBill and Melinda Gates FoundationCompleted
-
University of California, San FranciscoNational Eye Institute (NEI); Programme National de Santé Oculaire (PNSO)Recruiting
-
University of California, San FranciscoNational Eye Institute (NEI); Emory University; The Carter Center; Amhara Public...Recruiting
-
London School of Hygiene and Tropical MedicineUniversity College London Hospitals; World Health Organization; RTI International and other collaboratorsTerminated
-
London School of Hygiene and Tropical MedicineFederal Minstry of Health of Ethiopia; Oromia Regional Health Bureau, Ethiopia and other collaboratorsCompletedTrachomaUnited Kingdom, Ethiopia
-
Johns Hopkins UniversityNational Eye Institute (NEI)Completed
-
Johns Hopkins UniversityWellcome TrustCompletedTrachomaUnited States
Clinical Trials on CTH522-CAF01 IM
-
Statens Serum InstitutImperial College LondonCompletedChlamydia TrachomatisUnited Kingdom
-
Statens Serum InstitutCompleted
-
Statens Serum InstitutEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Ministry...CompletedAids, Cdc Group IGuinea-Bissau
-
University of Illinois at ChicagoCompletedIntensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies (IM-TMI)Acute Myeloid Leukemia | Chronic Myeloid Leukemia | Acute Leukemia | Lymphoblastic Leukemia | Non Hodgkins LymphomaUnited States
-
Fundación Eduardo AnituaRecruiting
-
University Hospitals, LeicesterPublic Health England; Crucell Holland BV; National Institute of Biological Standards...Completed
-
CurvaFix, Inc.RecruitingPelvic Fracture | Acetabular Fracture | Pelvic Ring Fracture | Pelvic Fracture AcetabulumUnited States
-
AstraZenecaCompletedHealthy Volunteer | Coronavirus Disease 2019 (COVID-19)China
-
Children's Fractures Interest Group, DenmarkRecruitingChild, Only | Implant Complication | Forearm Fracture | Fracture Healing | Fracture Fixation, IntramedullaryDenmark
-
Stryker Japan K.K.Unknown